#USA #New York #Securities Fraud #Pomerantz Law Firm #Agios Pharmaceuticals

Pomerantz Law Firm Investigates Agios Pharmaceuticals

The Pomerantz Law Firm, renowned for its expertise in corporate and securities class litigation, has initiated an investigation regarding Agios Pharmaceuticals, Inc. (NASDAQ: AGIO). This inquiry centers on allegations that Agios and certain executives may have engaged in securities fraud or other unlawful business practices affecting investors.

Recent Events Surrounding Agios Pharmaceuticals

On September 4, 2025, Agios announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) for its product PYRUKYND® (mitapivat). This drug, which is designed for treating non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha or beta-thalassemia in adult patients, will now face a review delay of three months, pushing the crucial decision date to December 7, 2025. This news sent shockwaves through the market, leading to a significant drop in Agios's stock price, which fell by $4.48, or 11.03%, to close at $36.13 on the same day.

The Investigation Details

Pomerantz is currently reaching out to investors impacted by this recent downturn. Those on the receiving end of financial losses related to Agios Pharmaceuticals are being urged to contact Danielle Peyton at Pomerantz for more information. This investigation aims to assess the potential implications of the FDA's decision and how it impacts shareholders. Investors are encouraged to consider their rights and gather information regarding possible legal actions.

The Legacy of Pomerantz Law Firm

Founded more than eight decades ago, the Pomerantz Law Firm remains a leader in the field of securities class actions and has achieved numerous multi-million dollar settlements on behalf of affected investors. Known for championing the rights of shareholders and holding corporations accountable for fraudulent activities, the firm has a storied history within the legal community. Founded by Abraham L. Pomerantz, regarded as a pioneer in the field of class action law, the firm continues to uphold his legacy by providing expert representation to victims of corporate misconduct.

Impact on Investors

The implications of this investigation could be substantial for Agios investors. Should evidence of wrongdoing arise, affected shareholders may have the opportunity to recover some of their financial losses through potential class action lawsuits. The Pomerantz firm’s experience in these matters could prove crucial for investors seeking justice.

Next Steps for Investors

Investors should remain vigilant and keep informed about ongoing developments regarding Agios Pharmaceuticals. If you have suffered from a loss on your investment, consider contacting Pomerantz Law Firm to discuss the circumstances of your case and determine if participation in the class action suit is appropriate.

For further information or to become part of the investigation, interested parties can reach Danielle Peyton at Pomerantz via email or by phone. The firm is committed to uncovering the truth behind the practices of Agios and ensuring that investors' rights are protected.

Conclusion

The situation surrounding Agios Pharmaceuticals highlights the volatility and risks present in the biopharmaceutical sector, particularly when regulatory decisions come into play. As the investigation progresses, all eyes will be on Agios and the Pomerantz Law Firm as they navigate these complex legal waters, which could shape the future of those financially tied to the company.